Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Thoracic 1

Conditions

Brain Neoplasms 3Meningeal Carcinomatosis 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 53Bevacizumab 45Radiotherapy 28Radiosurgery 21Carboplatin 14Erlotinib Hydrochloride 11Radiation 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Etoposide 9Vorinostat 8Trastuzumab 8Irinotecan 8Sunitinib 7Sorafenib 7Radiotherapy, Intensity-Modulated 7Lomustine 7Lapatinib 7Capecitabine 7dabrafenib 6Ipilimumab 6Imatinib Mesylate 6Cyclophosphamide 6Sirolimus 5Hydroxyurea 5Everolimus 5Bortezomib 5temsirolimus 4cabozantinib 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Brain Neoplasms × XL647 × Clear all
NCT02154529 2022-04-27

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Kadmon Corporation, LLC

Phase 1/2 Terminated
17 enrolled 19 charts
CNS

Brain Neoplasms

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02844439 2021-09-22

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Kadmon Corporation, LLC

Phase 2 Completed
40 enrolled 25 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡